AML - acute myeloid leukemia

This trial tests a new type of cell therapy for people with acute myeloid leukemia (AML) or blastic plasmacytoid dendritic cell neoplasm (BPDCN) that has come back or not responded to standard treatment. The therapy uses a patient's own natural killer (NK) cells, engineered to re…

This study tests two chemotherapy drugs, treosulfan and melphalan, given before a stem cell transplant in 220 adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to see which drug works better at helping patients survive longer with fewer side …

This early-phase trial tests a new treatment called CD64 CAR T cells for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to target and attack leukemia cells. The m…

This pilot study tests whether drinking tea made from soursop leaves can reduce the number of cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) — blood cancers that have not responded to standard treatments. About 20 particip…

This study tests an experimental oral medicine called CHM-029 in adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments, and that carries specific genetic changes (NPM1 mutations or KMT2A/NUP98 rearrangements). The main goals are to fin…

This phase 3 trial tests whether combining the targeted drug venetoclax with either a short course of decitabine or a modified DA regimen (daunorubicin and cytarabine) works better than the standard 3+7 DA regimen for adults newly diagnosed with acute myeloid leukemia. About 291 …

This study is testing a new way to do stem cell transplants for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). It combines stem cells from a half-matched donor (haploidentical) with cord blood, given at different times. The goal is to help …

This study tests a daily pill called ivosidenib in about 20 adults with a specific genetic form of acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who cannot receive a stem cell transplant. The goal is to see if the drug can keep the cancer from coming ba…

This study tests a combination of five drugs (venetoclax, azacitidine, cytarabine, idarubicin, and G-CSF) as a first treatment for adults aged 18-70 with acute myeloid leukemia (AML) who are healthy enough for strong chemotherapy. The goal is to see how many patients achieve comp…

This early-phase trial is testing a new drug called CBX-250 in people with certain blood cancers (like acute myeloid leukemia) that have come back or not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 72 participants …

This phase II trial tests whether the drug chidamide can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 134 adults with high-risk AML who are in remission after transplant will either take chidamide pills or receive standard observa…

This study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…

This study is for 80 adults with blood cancers like MDS or AML who are starting treatment. Participants wear a smartwatch and answer questionnaires to track their activity, symptoms, and quality of life. The goal is to help doctors better understand when patients need blood trans…

This study aims to develop a faster way to test new drug combinations for acute myeloid leukemia (AML). Researchers will take blood and bone marrow samples from 25 adults with AML and grow their cancer cells in special mice. They will then test how well standard treatments work i…